Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis

Seminars in Arthritis and Rheumatism

Volumn 47, Issue 1, 2017, Pages 108-114

  Iannone, Florenzo ^a   Santo, Leonardo ^b   Anelli, Maria Grazia ^a   Bucci, Romano ^c   Semeraro, Angelo ^d   Quarta, Laura ^e   D'Onofrio, Francesca ^f   Marsico, Antonio ^d   Carlino, Giorgio ^g   Casilli, Oriana ^e   Cacciapaglia, Fabio ^a   Zuccaro, Carmelo ^h   Falappone, Paola Chiara ⁱ   Cantatore, Francesco Paolo ^f   Muratore, Maurizio ^e   Lapadula, Giovanni ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Unità Operativa di Reumatologia   (Italy)

^c Rheumatology Hospital Unit   (Italy)

^d ASL Taranto   (Italy)

^e VITO FAZZI HOSPITAL   (Italy)

^f UNIVERSITY OF FOGGIA   (Italy)

^g Rheumatology Service   (Italy)

^h Ambulatorio di Reumatologia Ospedale di Brindisi   (Italy)

ⁱ SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

Author keywords

Drug survival; Golimumab; Predictors; Rheumatoid arthritis; Safety; Spondyloarthritis

Indexed keywords

GOLIMUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BREAST CANCER; CEREBROVASCULAR DISEASE; DISEASE DURATION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HERPES ZOSTER; HUMAN; LONGITUDINAL STUDY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; NEUTROPENIA; OBSERVATIONAL STUDY; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIATIC ARTHRITIS; RASH; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX DIFFERENCE; SPONDYLARTHRITIS; SURVIVAL; THROMBOCYTOPENIA; TOOTH ABSCESS; TREATMENT INTERRUPTION; TREATMENT OUTCOME; AGED; ANTAGONISTS AND INHIBITORS; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; SEX FACTOR; TIME FACTOR;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOLOGIC FACTORS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SPONDYLARTHRITIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85012866678     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2017.01.008     Document Type: Article

References (28)

1. Zink, A., Strangfeld, A., Schneider, M., Herzer, P., Hierse, F., Stoyanova-Scholz, M., et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 54 (2006), 3399–3407.
2. Iannone, F., Gremese, E., Atzeni, F., Biasi, D., Botsios, C., Cipriani, P., et al. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 39 (2012), 1179–1184.
3. Neovius, M., Arkema, E.V., Olsson, H., Eriksson, J.K., Kristensen, L.E., Simard, J.F., et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 74 (2015), 354–360.
4. Iannone, F., Lopriore, S., Bucci, R., Lopalco, G., Chialà, A., Cantarini, L., Lapadula, G., Longterm clinical outcomes in 420 patients with psoriatic arthritis taking anti-tumor necrosis factor drugs in real-world settings. J Rheumatol 43 (2016), 911–917.
5. Lie E, Kristensen LE, Forsblad-d'Elia H, Zverkova-Sandström T, Askling J, Jacobsson LT, et al. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis 2015;74:970-8.
6. Carmona, L., Gómez-Reino, J.J., BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther, 8, 2006, R72.
7. Keystone, E.C., Genovese, M.C., Klareskog, L., Hsia, E.C., Hall, S.T., Miranda, P.C., et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 68 (2009), 789–796.
8. Kavanaugh, A., McInnes, I., Mease, P., Krueger, G.G., Gladman, D., Gomez-Reino, J., et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60 (2009), 976–986.
9. Inman, R.D., Davis, J.C., Heijde, Dv, Diekman, L., Sieper, J., Kim, S.I., et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58 (2008), 3402–3412.
10. Sieper, J., van der Heijde, D., Dougados, M., Maksymowych, W.P., Scott, B.B., Boice, J.A., et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol 67 (2015), 2702–2712.
11. Keystone, E., Genovese, M.C., Klareskog, L., Hsia, E.C., Hall, S., Miranda, P.C., et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 69 (2010), 1129–1135.
12. Braun, J., Deodhar, A., Inman, R.D., van der Heijde, D., Mack, M., Xu, S., et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 71 (2012), 661–667.
13. Kavanaugh, A., McInnes, I.B., Mease, P.J., Krueger, G.G., Gladman, D.D., van der Heijde, D., et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis 72 (2013), 1777–1785.
14. Keystone, E.C., Genovese, M.C., Hall, S., Miranda, P.C., Bae, S.C., Palmer, W., et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. J Rheumatol 40 (2013), 1097–1103.
15. Kavanaugh, A., McInnes, I.B., Mease, P., Krueger, G.G., Gladman, D., van der Heijde, D., et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis 73 (2014), 1689–1694.
16. Deodhar, A., Braun, J., Inman, R.D., van der Heijde, D., Zhou, Y., Xu, S., et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis 74 (2015), 757–761.
17. Keystone, E.C., Genovese, M.C., Hall, S., Bae, S.C., Han, C., Gathany, T.A., et al. Safety and efficacy of subcutaneous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: final 5-year results of the GO-FORWARD trial. J Rheumatol 43 (2016), 298–306.
18. Dalén, J., Svedbom, A., Black, C.M., Lyu, R., Ding, Q., Sajjan, S., et al. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int 36 (2016), 1–9.
19. Aletaha, D., Neogi, T., Silman, A.J., Funovits, J., Felson, D.T., Bingham, C.O., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69 (2010), 1580–1588.
20. Taylor, W., Gladman, D., Helliwell, P., Marchesoni, A., Mease, P., Mielants, H., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54 (2006), 2665–2673.
21. Rudwaleit, M., van der Heijde, D., Landewé, R., Listing, J., Akkoc, N., Brandt, J., et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68 (2009), 777–783.
22. Rudwaleit, M., van der Heijde, D., Landewé, R., Akkoc, N., Brandt, J., Chou, C.T., et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70 (2011), 25–31.
23. Kavanaugh, A., van der Heijde, D., Beutler, A., Gladman, D., Mease, P., Krueger, G.G., et al. Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res (Hoboken) 68 (2016), 267–274.
24. Iannone, F., Lopalco, G., Rigante, D., Orlando, I., Cantarini, L., Lapadula, G., Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. Autoimmun Rev 15 (2016), 447–450.
25. Aletaha, D., Funovits, J., Keystone, E.C., Smolen, J.S., Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 56 (2007), 3226–3235.
26. Iannone, F., Carlino, G., Marchesoni, A., Sarzi-Puttini, P., Gorla, R., Lapadula, G., et al. Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA. Joint Bone Spine 83 (2016), 721–725.
27. Smolen, J.S., Kay, J., Doyle, M.K., Landewé, R., Matteson, E.L., Wollenhaupt, J., et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374 (2009), 210–221.
28. Shono, E., Effectiveness of golimumab in clinical management of patients with rheumatoid arthritis. Drugs R D 13 (2013), 95–100.